Jump to navigation

Free Newsletter Modern Trader Follow

Main menu

  • Futures
    • Modern Trader Magazine
    • Commodities
    • Futures Mag Archives
    • ETFs
    • Financials
    • Forex
    • Managed Funds
    • Market Analysis
    • News
    • Options
    • Regulation
    • Technology
    • Trading Strategies
    • Education
    • Futures Op-Ed
  • Favorites
    • Alpha Pages Most Popular
    • Futures Magazine
    • Modern Trader Magazine
    • Most Popular
    • Slideshows & Lists
    • Special Topics
      • Alpha Hunters
      • Bad Boys
      • FINtech
      • High-Frequency Trading
      • Trader's Life
      • Trading Strategies
      • FUTURES MAG's 500th ISSUE
      • We asked traders
  • Traders
    • Market Data
    • Hot Charts
    • Interactive Charts
    • Trading Calendar
  • FINalternatives
  • Hard Assets
    • Home
    • Base Metals
    • Precious Metals
    • Rare Earth Metals
    • Commodities
    • Mining Investments
    • Slideshows
  • Modern Trader
    • Subscribe
    • Past Issues
  • All +
    • Follow Us +
      • FuturesMag
      • Newsletters
      • Facebook
      • Google+
      • Linkedin
      • Twitter
      • RSS Feeds
    • About Us +
      • About
      • Advertise
      • Contact
      • Contribute
      • Privacy Policy
  • !
Follow Futures          
       
more >>

We Asked Traders

We asked traders for their opinion on the launch of bitcoin futures

Sponsored Content

Trading

Equities.com launches unlimited trading via Tradier Brokerage, Transforming into a news & fintech portal

Featured Topics

more Commodities>>

Commodities

Energy demand steps back in play
Advertisement
more Volatility>>

Volatility

Volatility & opportunity in the energy sector
more Financials>>

Financials

Daily Price Action: E-mini S&P 500
more Options>>

Options

Trading Vertical Option Spreads

Allergan calls $54 billion bid "undervalued"

By Drew Armstrong and Sonali Basak, Bloomberg

June 10, 2014 • Reprints

Allergan Inc., the maker of the Botox wrinkle treatment, rejected an increased bid of about $54 billion from Valeant Pharmaceuticals International Inc. and investor Bill Ackman, calling it undervalued.

Allergan, based in Irvine, California, said in a statement that it turned down the offer of $72 a share in cash and 0.83 a share of Valeant stock. On May 28, Laval, Quebec-based Valeant raised its bid for the first time to $49.4 billion from $45.7 billion.

“Valeant’s revised proposal substantially undervalues Allergan,” Allergan Chief Executive Officer David Pyott said in a statement today. “We do not believe Valeant’s proposal reflects Allergan’s growth prospects, nor does it offer sufficient or certain value to warrant discussions between Allergan and Valeant.”

Allergan shares fell 1.7% to $161.35 at 8:37 a.m. during early trading in New York.

Pershing Square Capital Management LP, Bill Ackman’s hedge fund, is using its own 9.7% ownership to push the sale. It has filed to start the process for a special shareholder meeting to remove most of Allergan’s board to get the deal done.

If Allergan’s management and board of directors choose not to discuss the deal, “a new board, appointed by shareholders, will negotiate a transaction,” Ackman said in a June 2 conference call with investors. Pershing Square agreed to forego the cash portion of the bid to boost the incentive for other shareholders.

The Allergan deal would be Valeant’s largest, as part of Valeant Chief Executive Officer Michael Pearson’s goal of joining the ranks of the world’s five biggest drugmakers by the end of 2016. The deal would eclipse the $8.7 billion purchase of Bausch & Lomb Inc. last year.

“We will be patient, we will get this deal done,” Pearson said on the June 2 conference call. “We believe that speed in concluding a transaction is in the best interest of both shareholders.”

About the Author

Copyright 2014 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Related Articles
Market events to watch this week
Central Bank comments boost US dollar
Gold prices dig deeper
Next week’s major market ranges: Story’s still the euro
Potentially dovish ECB could accelerate EUR/USD’s breakdown
Previous
Iranian gas market opening, if price is right
Next
What's driving the U.S. Dollar?
Related Terms
California 1387Quebec 880Allergan Inc. 10Bill Ackman 10Valeant Pharmaceuticals International Inc. 8Allergan 7Takeover 5Pershing Square Capital Management LP 4Bausch & Lomb Inc. 3botox 2bids 2David Pyott 1Michael Pearson 1

Free Newsletter Modern Trader Follow

Main menu

  • Futures
    • Modern Trader Magazine
    • Commodities
    • Futures Mag Archives
    • ETFs
    • Financials
    • Forex
    • Managed Funds
    • Market Analysis
    • News
    • Options
    • Regulation
    • Technology
    • Trading Strategies
    • Education
    • Futures Op-Ed
  • Favorites
    • Alpha Pages Most Popular
    • Futures Magazine
    • Modern Trader Magazine
    • Most Popular
    • Slideshows & Lists
    • Special Topics
      • Alpha Hunters
      • Bad Boys
      • FINtech
      • High-Frequency Trading
      • Trader's Life
      • Trading Strategies
      • FUTURES MAG's 500th ISSUE
      • We asked traders
  • Traders
    • Market Data
    • Hot Charts
    • Interactive Charts
    • Trading Calendar
  • FINalternatives
  • Hard Assets
    • Home
    • Base Metals
    • Precious Metals
    • Rare Earth Metals
    • Commodities
    • Mining Investments
    • Slideshows
  • Modern Trader
    • Subscribe
    • Past Issues
  • All +
    • Follow Us +
      • FuturesMag
      • Newsletters
      • Facebook
      • Google+
      • Linkedin
      • Twitter
      • RSS Feeds
    • About Us +
      • About
      • Advertise
      • Contact
      • Contribute
      • Privacy Policy
  • !
images